MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-23
SponsorChildren's Hospital Medical Center, Cincinnati

About this trial

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.

Eligibility criteria

Qualifiers

Age 6-23 years old.

Established or suspected clinical diagnosis of AIH or PSC.

Disqualifiers

History of liver transplantation.

Chronic Hepatitis B or untreated hepatitis C virus infection.

Pregnancy.

Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia).

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

115 Participants
are grouped into 1 trial group